

EDDECT OF EDIREX-SANOVEL (PIOGLITAZONE) MEDICATION ON THE INCIDENCE OF DEMENTIA

Vera Kapetivadze, R. Tabukashvili, N. Gegeshidze, Kh. Tchaava, T. Lazashvili, Z. Magapheridze, Z. Grigorashvili
Department of Internal Medicine, Tbilisi State Medical University, Georgia
verakap@rambler.ru

OBJECTIVE:

Peroxisome proliferator activated receptor γ -activating drugs show various salutary effects in preclinical models of neurodegenerative disease. The decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-oriented data sources.

METHODS:

Using observational data from 2012-2015, we analyzed the association of Edirex-Sanovel (pioglitazone) and incidence of dementia in a prospective cohort study of 45 subjects aged ≥ 60 years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus. We distinguished between nondiabetics, diabetics without Edirex-Sanovel, diabetics with prescriptions of 6 calendar quarters of Edirex-Sanovel, and diabetics with ≥ 6 quarters. Cox proportional hazard models explored the relative risk (RR) of dementia incidence dependent on edirex-sanovel use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidities.

RESULTS:

Long-term use of pioglitazone was associated with a lower dementia incidence. Relative to nondiabetics, the cumulative long-term use of Edirex-Sanovel reduced the dementia risk by 49% (RR = 0.50, $p = 0.027$). If diabetes patients used Edirex-Sanovel 6 quarters, the dementia risk was comparable to those of nondiabetics (RR = 1.20, $p = 0.36$), and diabetes patients without a Edirex-Sanovel treatment had a 25% increase in dementia risk (RR = 1.27, $p = 0.001$). We did not find evidence for age effects, nor for selection into Edirex-Sanovel treatment due to obesity.

INTERPRETATION:

These findings indicate that Edirex-Sanovel treatment is associated with a reduced dementia risk in initially non-insulin-dependent diabetes mellitus patients. Prospective clinical trials are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.